Prostate cancer management in Southeast Asian countries: A survey of clinical practice patterns

• Main Authors: Chiong, Edmund, Saad, Marniza, Hamid, Agus Rizal A. H., Ong-Cornel, Annielyn Beryl, Lojanapiwat, Bannakij, Pripatnanont, Choosak, Serrano, Dennis, Songco, Jaime, Sin, Loh Chit, Hakim, Lukman, Chua, Melvin Lee Kiang, Nguyen, Nguyen Phuc, Phuong, Pham Cam, Patnaik, Ravi Sekhar, Umbas, Rainy, Kanesvaran, Ravindran
• Format: Article
• Published: Sage 2024
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://eprints.um.edu.my/44192/; https://doi.org/10.1177/17588359231216582
• Institution: Universiti Malaya

Background:Prostate cancer (PC) has a serious public health impact, and its incidence is rising due to the aging population. There is limited evidence and consensus to guide the management of PC in Southeast Asia (SEA). We present real-world data on clinical practice patterns in SEA for advanced PC care.Method:A paper-based survey was used to identify clinical practice patterns and obtain consensus among the panelists. The survey included the demographics of the panelists, the use of clinical guidelines, and clinical practice patterns in the management of advanced PC in SEA.Results:Most panelists (81%) voted prostate-specific antigen (PSA) as the most effective test for early PC diagnosis and risk stratification. Nearly 44% of panelists agreed that prostate-specific membrane antigen positron emission tomography-computed tomography imaging for PC diagnostic and staging information aids local and systemic therapy decisions. The majority of the panel preferred abiraterone acetate (67%) or docetaxel (44%) as first-line therapy for symptomatic mCRPC patients. Abiraterone acetate (50%) is preferred over docetaxel as a first-line treatment in metastatic castration-sensitive prostate cancer patients with high-volume disease. However, the panel did not support the use of abiraterone acetate in non-metastatic castration-resistant prostate cancer (nmCRPC) patients. Apalutamide (75%) is the preferred treatment option for patients with nmCRPC. The cost and availability of modern treatments and technologies are important factors influencing therapeutic decisions. All panelists supported the use of generic versions of approved therapies.Conclusion:The survey results reflect real-world management of advanced PC in a SEA country. These findings could be used to guide local clinical practices and highlight the financial challenges of modern healthcare.